| abstract |
[57] Most current vaccination strategies still use relatively crude products, such as attenuated or inactivated viruses. Such vaccines often produce both antibody-mediated and cell-mediated immunity and cannot modify the type of immune response that occurs. In the therapeutic method of the present invention, a short-chain peptide (preferably non-allele-restricted) modeled on the high-affinity immunomodulatory self-peptide of the present invention is added to the APC of a patient. be introduced. Since the peptides of the present invention bind to a variety of class II isotypes, classification of the tissue type that determines the particular class II allele expressed by the patient may not be necessary. |